Cost-Utility of Anti-Vascular Endothelial Growth Factor Treatment for Macular Edema Secondary to Central Retinal Vein Occlusion.

ABSTRACT:

Purpose

To evaluate the cost-utility of treatment for macular edema in central retinal vein occlusion (CRVO) using intravitreal injections of the anti-vascular endothelial growth factor (VEGF) agents bevacizumab, ranibizumab, and aflibercept.

Design

Decision analysis model of cost-utility.

Participants

Data from study participants in the Lucentis, Eylea, Avastin in Vein Occlusion (LEAVO) study.

Methods

A decision analysis of a disease simulation model was used to calculate comparative cost-utility of intravitreal bevacizumab (IVB), intravitreal ranibizumab (IVR), and intravitreal aflibercept (IVA) for the treatment of macular edema associated with CRVO based on data from the LEAVO study. Center for Medicare and Medicaid Services data were used to calculate asso

SUBMITTER: Lin J 

PROVIDER: S-EPMC8004537 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature